Bayer

Bayer Boosts Women’s Healthcare with Kandy Buy

Bayer is to acquire UK biotech Kandy Therapeutics in a move that will expand its drug development pipeline in women’s healthcare.

Bayer Loses Round One of Roundup Appeals

In the ongoing litigation over whether Monsanto’s Roundup herbicide causes cancer, Bayer has suffered another setback, losing its appeal of the first of three US jury verdicts against it – even though the California Court of Appeals in San Francisco further slashed the 2018 damage award to $20.4 million.

Bayer Backs Away from Roundup Science Panel

Bayer has backed away from plans to create a science advisory panel to help decide still outstanding claims from US plaintiffs that Monsanto’s glyphosate-based herbicide Roundup caused their non-Hodgkins lymphoma.

Part of Bayer’s Roundup Settlement Questioned

Bayer’s relief over its recent deal to settle three-quarters of its outstanding Roundup-related US lawsuits for more than $10 billion altogether could be short-lived.

Bayer Agrees $9 Billion Roundup Settlement

After nearly a year of deliberation, Bayer has clinched a deal to settle three-quarters of its outstanding lawsuits from US plaintiffs who claim that Monsanto’s top-selling herbicide Roundup with the active ingredient glyphosate caused their non-Hodgkins lymphoma (NHL).

Bayer Halts Work on US Dicamba Facility

Bayer has halted work on a $1 billion production facility for the herbicide active ingredient dicamba in the US state of Louisana but said the decision was not related to a court order mandating that the Environmental Protection Agency (EPA) vacate its approval of the crop protectant active ingredient.

EPA Brushes Over Most of Court Dicamba Ruling

EU Approves Sale of Bayer Animal Health to Elanco

Bayer Seen in Verbal Roundup Settlements

Lanxess Completes Sale of its Currenta Stake

German specialty chemicals producer Lanxess completed the sale of its 40% stake in chemical park operator Currenta to Australia’s Macquarie Infrastructure and Real Assets (MIRA) at the end of April. The sale agreement was concluded in August 2019.

Bayer Biding its Time on Roundup Settlements

Bayer has set aside €480 million to defend lawsuits brought by people who claim that Monsanto’s glyphosate-based herbicide Roundup caused their non-Hodgkins lymphoma, CEO Werner Baumann said at the company’s annual general meeting on Apr. 28.

Agrochemical and Custom Manufacturing Industry: Connected Fates

The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.

Concerns about Bayer’s Chloroquine Donation

Trump’s Promotion of COVID Cure is Media Fodder

Bayer Settles Roundup Labeling Class Action

Bayer Collaborates with Curadev

Bayer Said Ready for Roundup Settlement

Heart Association Slammed for Bayer Promotion

Bayer Agrees to M&A Special Audit

Winkeljohann to Succeed Wenning as Bayer Board Chair

Azelis, Corteva and Sika to join Together for Sustainability Initiative

Bayer and BASF Lose $265 Million Dicamba Case

Bayer and Meiogenix in Crop Collaboration

Bayer Close to $10 Billion Roundup Settlement?

Schrödinger and Bayer to Collaborate on Acceleration of Drug Discovery

Wuxi Biologics to Take Bayer Plant at Leverkusen

Bayer’s Vitravki Faces Pricing Hurdles

Thiacloprid now Effectively Banned in the EU

Bayer to Appeal Hardeman Roundup Verdict

Lanxess Managing Board Gets Female Member

FTC Move Delays Bayer-Elanco Deal

Innovative Chemistry Between Mountains and Lakes

Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.

The Chemical and Pharmaceutical Industry in Eastern Germany

Bayer Agrees to Delay two more Roundup trials

Made in Switzerland – Exported Worldwide